Liver Cancer
Conditions
Brief summary
This is a open-label, single center, cohort study to determine the efficacy and safety of IM83 CAR-T cells in patients with advanced Liver Tumors.
Interventions
BIOLOGICALIM83 CAR-T cells
3×10\^9 CAR-T cells
COMBINATION_PRODUCTThe second-line treatment of liver cancer
approved by NMPA
Sponsors
Beijing Immunochina Medical Science & Technology Co., Ltd.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* ≥ 18 years old, male or female. * Patients with advanced hepatocellular carcinoma (HCC) diagnosed by histopathology or cytology, Barcelona stage B-C. * Progression or intolerance after receiving standardized systematic treatment in the past (at least first-line treatment fails, and PD-1 / PD-L1 drugs can be used). * Patients in car-t combined treatment group need to have not received the combined drugs before. * At least one measurable target lesion according to RECIST1.1. * Tumor cells expressed GPC3 antigen. * Child Pugh score of liver function ≤ 7. * ECOG 0-1. * Estimated survival ≥ 12 weeks; * Laboratory inspection shall at least meet the following specified indicators: ANC≥ 1.5 × 10 \^ 9 / L，platelet ≥ 75 × 10 \^ 9 / L ，Hemoglobin ≥ 90 g / L，Serum creatinine ≤ 1.5 ULN，serum bilirubin ≤ 3 ULN，INR≤ 2，AST and ALT)≤ 5.0 ULN，Creatinine clearance rate ≥ 60 ml / min. * The left ventricular ejection fraction was \> 50%.
Exclusion criteria
* The researcher has determined that the subject has autoimmune diseases that are not suitable to participate in this study, such as systemic lupus erythematosus, rheumatoid arthritis, ulcerative colitis. * History of epilepsy or other central nervous system diseases that may affect the test in the judgment of the investigator. * The washout period of chemotherapy, molecular targeted therapy, immunotherapy, hepatic artery chemoembolization, radiofrequency ablation, radiotherapy for non target lesions or other anti-tumor drugs within 1 week before blood collection is less than 5 half lives. * Systemic glucocorticoids (local use is allowed) or other immunosuppressants were used within 3 days before apheresis. * Other incurable malignant tumors in the past 5 years or at the same time, except cervical carcinoma in situ, skin basal cell carcinoma and breast ductal carcinoma in situ. * The investigator assessed that the subject had poorly controlled pleural effusion, ascites or pericardial effusion. * Hypertension with poor drug control (systolic blood pressure \> 160mmhg and / or diastolic blood pressure \> 90mmHg) or cardiovascular and cerebrovascular diseases with clinical significance (such as active) within 6 months before signing the informed consent, such as cerebrovascular accident, myocardial infarction, unstable angina pectoris, or severe arrhythmia, which cannot be controlled by drugs or has potential impact on the study treatment. * Combined with other serious organic diseases or mental diseases. * Subjects with HBsAg or HBcAbpositive and peripheral blood HBV DNA titers of \>2000 IU/ml (HBsAg positive but HBV DNA titer \<2000 IU/ml of peripheral blood and eligible for antiviral treatment according to chronic hepatitis B prevention guideline 2019 Edition). HCV antibody positive and HCV RNA in peripheral blood \> 500 IU / ml. Syphilis antibody positive. * Male subjects who are pregnant or breastfeeding during the screening period, or who plan pregnancy during treatment or within 1 year after the end of treatment, or whose partner plans pregnancy within 1 year after the end of treatment. * There were active or uncontrollable infections requiring systemic treatment within 1 week before cell apheresis. * Other researchers believe that it is not suitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of adverse events (AEs) and abnormal laboratory test results as assessed by CTCAE V5.0 | Up to 28 days after CAR-T cell infusion |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Duration of Response (DOR) | Up to 24 weeks after CAR-T cell infusion | DOR, defined as the time from the first occurrence of a documented objective response to disease progression or death from any cause (whichever occurs first) in Stage 1, as determined by the investigator according to RECIST v1.1 |
| Progression-free survival (PFS) | Up to 24 weeks after CAR-T cell infusion | PFS, defined as the time from CAR-T cell infusion to the first occurrence of disease progression or death from any cause (whichever occurs first) , as determined by the investigator according to RECIST v1.1 |
| Objective response rate (ORR) | At 28 days, 3 months and 6 months after CAR-T cell infusion | ORR, defined as the proportion of participants with a complete response or partial response, as determined by the investigator according to RECIST v1.1 |
| Plasma levels of α fetoprotein (AFP) cells infusion | At 28 days, 3 months and 6 months after CAR-T cell infusion | — |
| Persistence of CAR-T cells (cell counts and cell percentage in peripheral blood) | Up to 24 weeks after CAR-T cell infusion | The persistence over time of CAR T cells in the peripheral blood as determined by flow cytometry and qPCR. |
| Overall survival (OS) | Up to 24 weeks after CAR-T cell infusion | OS , defined as the time from CAR-T cell infusion to death from any cause |
Countries
China
Contacts
Primary ContactFei Wu, MD
Outcome results
None listed